Wen et al. demonstrated that ATF3, a key transcriptional regulator in cardiovascular disease, suppresses advanced mitochondria-dependent apoptosis by upregulating its direct target BCL2, highlighting ATF3 as a potential therapeutic and prognostic marker in AAA [223]. This evidence concerns the gene BCL2 and triple-A syndrome.